BRIEF—New company targets immunotherapies for genetically-defined type 1 diabetes and other autoimmune diseases

ImmunoMolecular Therapeutics (IM Therapeutics), a company developing personalized small molecule therapies for genetically defined autoimmune diseases, has spun out from the Barbara Davis Center for Diabetes at the University of Colorado.

IM Therapeutics will seek to advance new therapeutic strategies for type 1 diabetes (T1D) that directly inactivate pathogenic immune cells responsible for damaging the insulin-producing beta cells in the pancreas.

Co-founder Peter Gottlieb said: “Our ultimate goal is to inhibit the initiation of an autoimmune response, thus maintaining normal insulin production.

“I am excited to be part of a company that could potentially reduce T1D patients’ lifelong dependence on insulin.”